An issue of Davita Inc (NYSE:DVA) bonds fell 1.6% as a percentage of their face value during trading on Thursday. The high-yield debt issue has a 5.125% coupon and will mature on July 15, 2024. The debt is now trading at $96.75 and was trading at $98.50 last week. Price changes in a company’s bonds in credit markets sometimes anticipate parallel changes in its stock price.
Separately, William Blair reiterated a “buy” rating on shares of Davita in a report on Wednesday, June 6th. One research analyst has rated the stock with a sell rating, five have given a hold rating, five have assigned a buy rating and two have given a strong buy rating to the company’s stock. Davita currently has an average rating of “Buy” and a consensus target price of $81.22.
NYSE:DVA opened at $69.44 on Friday. The company has a debt-to-equity ratio of 1.94, a quick ratio of 2.90 and a current ratio of 2.94. The company has a market capitalization of $12.24 billion, a price-to-earnings ratio of 20.92, a price-to-earnings-growth ratio of 1.02 and a beta of 1.10. Davita Inc has a 12-month low of $52.51 and a 12-month high of $80.71.
Davita (NYSE:DVA) last released its quarterly earnings data on Thursday, May 3rd. The company reported $1.05 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.92 by $0.13. The firm had revenue of $2.85 billion for the quarter, compared to analyst estimates of $2.79 billion. Davita had a return on equity of 13.84% and a net margin of 2.94%. The business’s revenue for the quarter was up 8.3% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.79 earnings per share. equities research analysts predict that Davita Inc will post 4.09 EPS for the current fiscal year.
In other Davita news, Director William L. Roper sold 1,505 shares of the company’s stock in a transaction that occurred on Tuesday, May 22nd. The stock was sold at an average price of $68.22, for a total value of $102,671.10. Following the sale, the director now owns 46,733 shares in the company, valued at $3,188,125.26. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Pamela M. Arway sold 1,264 shares of the company’s stock in a transaction that occurred on Thursday, June 7th. The shares were sold at an average price of $68.76, for a total value of $86,912.64. Following the completion of the sale, the director now owns 39,235 shares in the company, valued at approximately $2,697,798.60. The disclosure for this sale can be found here. Insiders sold 3,107 shares of company stock worth $211,976 in the last 90 days. Corporate insiders own 0.95% of the company’s stock.
Several institutional investors have recently bought and sold shares of DVA. Raymond James Financial Services Advisors Inc. grew its position in shares of Davita by 196.5% in the fourth quarter. Raymond James Financial Services Advisors Inc. now owns 18,710 shares of the company’s stock valued at $1,352,000 after purchasing an additional 12,399 shares during the last quarter. American International Group Inc. grew its position in shares of Davita by 13.7% in the fourth quarter. American International Group Inc. now owns 51,865 shares of the company’s stock valued at $3,747,000 after purchasing an additional 6,260 shares during the last quarter. Baird Financial Group Inc. acquired a new position in shares of Davita in the fourth quarter valued at approximately $1,686,000. State of Tennessee Treasury Department grew its position in shares of Davita by 31.1% in the fourth quarter. State of Tennessee Treasury Department now owns 54,573 shares of the company’s stock valued at $3,943,000 after purchasing an additional 12,954 shares during the last quarter. Finally, Standard Life Aberdeen plc grew its position in shares of Davita by 3.4% in the fourth quarter. Standard Life Aberdeen plc now owns 74,835 shares of the company’s stock valued at $5,408,000 after purchasing an additional 2,429 shares during the last quarter. 87.67% of the stock is currently owned by institutional investors.
DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
Receive News & Ratings for Davita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Davita and related companies with MarketBeat.com's FREE daily email newsletter.